Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.63 +0.04 (+6.78%)
As of 03:59 PM Eastern
Compare

MDNA vs. IPA, APM, GXE, CGC, and WMD

Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), and WeedMD (WMD). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to ImmunoPrecise Antibodies?

Medicenna Therapeutics (TSE:MDNA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImmunoPrecise Antibodies has higher revenue and earnings than Medicenna Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
ImmunoPrecise Antibodies Neutral

ImmunoPrecise Antibodies has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. ImmunoPrecise Antibodies' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
ImmunoPrecise Antibodies N/A N/A N/A

Summary

ImmunoPrecise Antibodies beats Medicenna Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Andean Precious Metals?

Medicenna Therapeutics (TSE:MDNA) and Andean Precious Metals (CVE:APM) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Andean Precious Metals shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Comparatively, 69.4% of Andean Precious Metals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Andean Precious Metals has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Andean Precious Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Andean Precious MetalsC$154.78M0.88C$37.41MC$0.512.55

In the previous week, Andean Precious Metals had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 1 mentions for Andean Precious Metals and 0 mentions for Medicenna Therapeutics. Andean Precious Metals' average media sentiment score of 0.80 beat Medicenna Therapeutics' score of 0.00 indicating that Andean Precious Metals is being referred to more favorably in the news media.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Andean Precious Metals Positive

Medicenna Therapeutics has a beta of 2.900601, meaning that its share price is 190% more volatile than the S&P 500. Comparatively, Andean Precious Metals has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Andean Precious Metals has a net margin of 16.17% compared to Medicenna Therapeutics' net margin of -533,640.00%. Andean Precious Metals' return on equity of 20.32% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Andean Precious Metals 16.17%20.32%4.13%

Summary

Andean Precious Metals beats Medicenna Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Gear Energy?

Medicenna Therapeutics (TSE:MDNA) and Gear Energy (TSE:GXE) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Medicenna Therapeutics has a beta of 2.900601, meaning that its share price is 190% more volatile than the S&P 500. Comparatively, Gear Energy has a beta of 3.52, meaning that its share price is 252% more volatile than the S&P 500.

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled Gear Energy'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Gear Energy Neutral

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 2.4% of Gear Energy shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Comparatively, 7.6% of Gear Energy shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Gear Energy 5.77%3.52%4.84%

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Medicenna Therapeutics (TSE:MDNA) and Canadian Gold (CVE:CGC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Canadian Gold N/A -92.98%-48.06%

Medicenna Therapeutics has a beta of 2.900601, meaning that its stock price is 190% more volatile than the S&P 500. Comparatively, Canadian Gold has a beta of -1.586234, meaning that its stock price is 259% less volatile than the S&P 500.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled Canadian Gold'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Canadian Gold Neutral

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Canadian Gold shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 43.3% of Canadian Gold shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Canadian Gold beats Medicenna Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

WeedMD (CVE:WMD) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Medicenna Therapeutics has lower revenue, but higher earnings than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
WeedMDN/A N/A N/A
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

In the previous week, WeedMD's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
WeedMD Neutral
Medicenna Therapeutics Neutral

Summary

WeedMD beats Medicenna Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$52.56MC$460.35MC$6.25BC$11.85B
Dividend YieldN/A3.86%2.78%6.24%
P/E Ratio-4.204.1320.8824.81
Price / SalesN/A7,426.61533.0114.18
Price / Cash1.1513.1343.2982.42
Price / Book8.4683.759.984.60
Net Income-C$25.98M-C$96.07MC$3.54BC$299.62M
1 Month Performance-3.08%2.74%4.68%3.55%
1 Year Performance-37.00%72.02%40.48%58.52%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.63
+6.8%		N/A-37.9%C$52.56MN/AN/A20
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/A+0.0%C$162.08MC$19.47MN/A80
APM
Andean Precious Metals
N/AC$1.29
+7.5%		N/A+0.0%C$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/A+110.5%C$126.35MN/AN/A3,150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
JPMorgan Just Made $6,300 Gold Call. Are You Exposed?
JPMorgan just raised its 2026 gold forecast to 6,300 - and outlined a credible path to 8,000 if everyday inves...
Vault Metal | Sponsoredtc pixel